mTOR, translation initiation and cancer
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Control of mRNA translation plays a fundamental role in many aspects of cell metabolism. It constitutes a critical step in the control of gene expression, and consequently cell growth, proliferation and differentiation. Translation is regulated in response to nutrient availability, hormones, mitogenic and growth factor stimulation and is coupled with cell cycle progression and cell growth. Signaling by the PI3K/Akt/mTOR pathway profoundly affects mRNA translation through phosphorylation of downstream targets such as 4E-BP and S6K. Inhibitors of this pathway and thus cap-dependent translation are emerging as promising therapeutic options for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such a shift has been associated with proliferation in tumorigenesis, and has been linked to the translational control of RPs (Mamane et al., 2006; Ruggero and Sonenberg, 2005).”
From Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes (2011) · cites this paper as Mamane et al., 2006
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 5×
“…factors and hormones) with aminoacid availability and intracellular energy status to control translation rates and additional metabolic processes (Hay and Sonenberg, 2004) (Figure 2). mTOR has received considerable attention, as rapamycin (Rapamune) is a specific inhibitor of mTOR activity (for…”
BackgroundInfluentialSelf-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185 · cited 1×
“An important downstream target of this signaling pathway is cap-dependent mRNA translation (Hay and Sonenberg, 2004; Hennessy et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the…”
BackgroundeIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationRegulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationHolz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,239 · cited 1×
“…Heat and Acid-Stable protein regulated by Insulin) and 4E-BP2, were identified in a screen using radiolabelled recombinant eIF4E protein to probe a human placenta expression library (Pause et al., 1994) and by sequencing the complementary DNA (cDNA) clone for PHAS-I (Hu et al., 1994).”
BackgroundSelf-citationMammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093 · cited 1×
“Enhancement of the eIF4E/4E-BP interaction, through the expression of a constitutively active 4E-BP mutant (all phosphorylation sites mutated to Ala), leads to a decrease in cell size and inhibition of cell cycle progression in a manner that mimics rapamycin treatment (Fingar et al., 2002, 2004).”
BackgroundKim, D.-H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V. P., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 961 · cited 1×
“…et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the 4E-BPs (Gingras et al., 2001; Jacinto and Hall, 2003; Kim et al., 2003; Ruggero and Pandolfi, 2003; Kim and Sabatini, 2004).”
BackgroundMalignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956 · cited 1×
“…binding (Gingras et al., 1999b). eIF4G recruits the 40S small ribosomal subunit to the mRNA through the ribosomeassociated eIF3. eIF4E eIF4E was the first translation factor shown to cause malignant transformation when overexpressed in cul- tured rodent cells (Lazaris-Karatzas et al., 1990).”
BackgroundSelf-citationSurvival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951 · cited 1×
“Furthermore, two groups independently demonstrated that eIF4E promotes lymphomagenesis in cooperation with Myc in transgenic mice (Ruggero et al., 2004; Wendel et al., 2004).”
Background
Cited by
Items 101–200 of 618
Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., Cappellini, A., Ognibene, A., & McCubrey, J. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.04.005 · Cited by 152
mTORC1 signalling and mRNA translation
Proud, C. G. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370227 · Cited by 131
S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1
Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B., & Karni, R. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.020 · Cited by 129
“…one of the major signaling pathways hyper activated in many cancers, and leads to uncontrolled proliferation, increased survival, motility and invasiveness of cancer cells (Mamane et al., 2006; Manning and Cantley, 2007; Yuan and Correspondence should be addressed to R.K. (rotemka@ekmd.huji.ac.il).”
BackgroundPP2A regulatory subunit PP2A-B' counteracts S6K phosphorylation
Hahn, K., Miranda, M., Francis, V. A., Vendrell, J., Zorzano, A., & Teleman, A. A. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.015 · Cited by 131
“Furthermore, S6K1, as one of the principal effectors of TOR-mediated tissue growth, has been linked to a number of cancers (Mamane et al., 2006).”
BackgroundCDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation
Shuda, M., Velásquez, C., Cheng, E., Cordek, D. G., Kwun, H. J., Chang, Y., & Moore, P. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505787112 · Cited by 127
“sT that were used for transient transfection experiments are previously described (1, 2).”
MethodJohansson, G., Mahller, Y. Y., Collins, M. H., Kim, M., Nobukuni, T., Perentesis, J. P., Cripe, T. P., Lane, H. A., Kozma, S. C., Thomas, G., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2335 · Cited by 147
“(S6K1 and S6K2) and the phosphorylation and inactivation of the eukaryotic initiation factor 4E binding proteins (4E-BP1 to 4E-BP3), resulting in enhanced translation (22).”
BackgroundS6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response
Lai, K. P., Leong, W. F., Chau, J. F. L., Jia, D., Zeng, L., Liu, H., He, L., Hao, A., Zhang, H., Meek, D. W., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.166 · Cited by 136
“Phosphorylation of eIF4B and rpS6 by S6K1, as well as phosphorylation of 4E-BP1 by mTOR, promotes global translation and cell growth (Averous and Proud, 2006; Mamane et al, 2006).”
BackgroundmTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer
Zhang, Y., Dai, Q., Sun, D., Xiong, H., Tian, X., Gao, F., Xu, M., Chen, G., Han, Z., & Fang, J. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0555-9 · Cited by 131
“In this regard, mTOR signaling activity is associated with cancer cell growth and survival.(7,8) As 1 of the 10 leading cancers, colorectal cancer (CRC) is also one of the major causes of cancer mortality Society of Surgical Oncology 2009”
BackgroundJo, O. D., Martin, J., Bernath, A., Masri, J., Lichtenstein, A. K., & Gera, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801185200 · Cited by 138
Yeo, W., Chan, S. L., Mo, F. K., Chu, C. M., Hui, J. W., Tong, J. H., Chan, A. W., Koh, J., Hui, E. P., Loong, H., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1334-6 · Cited by 125
“S6K1 participates in numerous cellular processes central to promoting cell proliferation, cell growth and cell cycle progression [34,35].”
BackgroundTargeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., Manzoli, L., & McCubrey, J. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903136775 · Cited by 120
“Therefore, mTORC1 regulates a variety of steps involved in protein synthesis, but in particular it controls the expression of molecules such as c-Myc, cyclin D1, cyclin-dependent kinase 2, retinoblastoma protein, hypoxia-inducible factor (HIF)-1α, ornithine decarboxylase, p27Kip1 and VEGF, which are key determinants o…”
BackgroundShor, B., Zhang, W.-G., Toral-Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., & Yu, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6487 · Cited by 119
Martelli, A. M., Chiarini, F., Evangelisti, C., Cappellini, A., Buontempo, F., Bressanin, D., Fini, M., & McCubrey, J. A. (2012) · Oncotarget · doi:10.18632/oncotarget.477 · Cited by 128
“eIF4E is critical for translating 5’capped mRNAs, that include transcripts mainly encoding for proliferation and survival promoting proteins, such as c-Myc, cyclin-dependent kinase-2 (CDK-2), cyclin D1, signal activator and transducer of transcription-3 (STAT-3), B-cell lymphoma (Bcl) -2, BclxL, survivin, myeloid cell…”
BackgroundThe splicing-factor oncoprotein SF2/ASF activates mTORC1
Karni, R., Hippo, Y., Lowe, S. W., & Krainer, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801376105 · Cited by 124
“T PI3K-mTOR pathway is an important contributor to the transformed phenotype and is activated in many cancers (1, 2).”
BackgroundMethodInfluentialOn the participation of mTOR in recognition memory
Myskiw, J. D. C., Rossato, J. I., Bevilaqua, L. R., Medina, J. H., Izquierdo, I., & Cammarota, M. (2007) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2007.10.002 · Cited by 142
Green, A. S., Chapuis, N., Lacombe, C., Mayeux, P., Bouscary, D., & Tamburini, J. (2011) · Cell Cycle · doi:10.4161/cc.10.13.16244 · Cited by 115
Kim, K.-K., Lee, J. J., Yang, Y., You, K.-H., & Lee, J.-H. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn031 · Cited by 115
Wei, Y.-N., Hu, H.-Y., Xie, G.-C., Fu, N., Ning, Z.-B., Zeng, R., & Khaitovich, P. (2015) · Genome Biology · doi:10.1186/s13059-015-0608-2 · Cited by 117
“Notably, all six genes showing discordant expression patterns within the PI3K-Akt-mTORC1 signaling cascade PI3K, Akt, mLST8, S6K1, eIF3e and eIF3f - were shown to function as mTOR pathway activators [59-62].”
BackgroundPan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
García, P. D., Langowski, J. L., Wang, Y., Chen, M., Castillo, J., Fanton, C. P., Ison-Dugenny, M., Zavorotinskaya, T., Dai, Y., Lü, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2062 · Cited by 127
The EGFR‐GEP100‐Arf6‐AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis†
Sabe, H., Hashimoto, S., Morishige, M., Ogawa, E., Hashimoto, A., Nam, J., Miura, K., Yano, H., & Onodera, Y. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00917.x · Cited by 113
“mTOR is one of the central kinases regulating 5’-capdependent translational control (26), and is frequently”
BackgroundUnique translation initiation of mRNAs-containing TISU element
Elfakess, R., Sinvani, H., Haimov, O., Svitkin, Y., Sonenberg, N., & Dikstein, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr484 · Cited by 115
“The cells were then incubated for 24 h either in a medium lacking amino acids or in a normal medium containing 20 nM rapamycin, a drug known to inhibit mTOR activity and the cap-binding factor eIF4E (26).”
Self-citationKojima, K., Shimanuki, M., Shikami, M., Samudio, I. J., Ruvolo, V. R., Corn, P. G., Hanaoka, N., Konopleva, M. Y., Andreeff, M., & Nakakuma, H. (2008) · Leukemia · doi:10.1038/leu.2008.158 · Cited by 124
Keum, Y., Khor, T. O., Lin, W., Shen, G., Kwon, K. H., Barve, A., Li, W., & Kong, A. N. T. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9948-5 · Cited by 123
“Protein synthesis is an energetically expensive and tightly regulated and controlled process at the level of initiation by modification of the eukaryotic initiation factors (eIFs), and the Akt/mTOR signaling pathway has emerged as an important regulator of protein synthesis due to its control in cap-dependent mRNA tra…”
Azoulay‐Alfaguter, I., Elya, R., Avrahami, L., Katz, A., & Eldar-Finkelman, H. (2014) · Oncogene · doi:10.1038/onc.2014.390 · Cited by 121
Tumorigenic activity and therapeutic inhibition of Rheb GTPase
Mavrakis, K. J., Zhu, H., Silva, R. L. A., Mills, J. R., Teruya-Feldstein, J., Lowe, S. W., Tam, W., Pelletier, J., & Wendel, H.-G. (2008) · Genes & Development · doi:10.1101/gad.1690808 · Cited by 113
“…the unique role of eIF4E as a translation factor capable of driving tumor development in vivo and are consistent with a rate-limiting role of eIF4E in the translation of transformation-relevant proteins (Polunovsky et al. 2000; Hay and Sonenberg 2004; Wendel et al. 2004; Mamane et al. 2007).”
BackgroundInfluentialCap‐Dependent Translation Initiation Factor e IF4E: An Emerging Anticancer Drug Target
Jia, Y., Polunovsky, V., Bitterman, P. B., & Wagner, C. R. (2012) · Medicinal Research Reviews · doi:10.1002/med.21260 · Cited by 107
Status of mTOR Activity May Phenotypically Differentiate Senescence and Quiescence
Cho, S., & Hwang, E. S. (2012) · Molecules and Cells · doi:10.1007/s10059-012-0042-1 · Cited by 95
“Recent studies indicate that the activity of mammalian target of rapamycin (mTOR), a factor that relays growth factor signal and induces cell growth by facilitating the initiation of protein synthesis (Mamane et al., 2006), is critical in determining cellular lysosome status by modulating their biogenesis and turnover.”
BackgroundZhang, H., Zhang, G., Gonzalez, F. J., Park, S.-M., & Cai, D. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001112 · Cited by 101
Fatty Acid Elongase 7 Catalyzes Lipidome Remodeling Essential for Human Cytomegalovirus Replication
Purdy, J. G., Shenk, T., & Rabinowitz, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.003 · Cited by 103
“mTOR complex 1 (mTORC1) kinase activity is required to maintain active translation (Mamane et al., 2006), and the kinase also controls key aspects of lipid metabolism via several mechanisms, including SREBP-1 activation (Laplante and Sabatini, 2009; Lewis et al.”
Harlan, S. M., Guo, D.-F., Morgan, D. A., Fernandes-Santos, C., & Rahmouni, K. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.017 · Cited by 99
“mTOR is critically involved in the regulation of a number of cellular functions, including protein synthesis, cell growth and proliferation, ribosome and mitochondria biogenesis, cytoskeleton organization, and autophagy (Hay and Sonenberg, 2004; Mamane et al., 2006; Wullschleger et al., 2006).”
BackgroundPalangat, M., Anastasakis, D. G., Fei, D. L., Lindblad, K. E., Bradley, R., Hourigan, C. S., Hafner, M., & Larson, D. R. (2019) · Genes & Development · doi:10.1101/gad.319590.118 · Cited by 102
“…viability after genotoxic stress leads to a population of cells which secrete IL8 for >30 d. Translation initiation is often misregulated in cancer (Mamane et al. 2006) and the translation machinery is tightly controlled at the posttranscriptional level through the mTOR pathway, which is…”
mTOR, linking metabolism and immunity
Xu, X., Ye, L., Araki, K., & Ahmed, R. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.12.005 · Cited by 96
“mTORC1 also directly up-regulates protein production by phosphorylation of the translational factor 4E-BP and the S6 kinase, as well as in promoting amino acid uptake [5, 67].”
BackgroundAhmad, F., Singh, K., Das, D., Gowaikar, R., Shaw, E., Ramachandran, A., Rupanagudi, K. V., Kommaddi, R. P., Bennett, D. A., & Ravindranath, V. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6860 · Cited by 100
“Akt1-mammalian target of rapamycin (mTOR) signaling mediates cap-dependent protein translation, which accounts for most of the protein translation occurring in the cell (30).”
Kong, D., Banerjee, S., Huang, W., Li, Y., Wang, Z., Kim, H.-R. C., & Sarkar, F. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3241 · Cited by 102
Slotkin, E. K., Patwardhan, P. P., Vasudeva, S. D., de Stanchina, E., Tap, W. D., & Schwartz, G. K. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0711 · Cited by 97
Moriceau, G., Ory, B., Mitrofan, L., Riganti, C., Blanchard, F., Brion, R., Charrier, C., Battaglia, S., Pilet, P., Denis, M. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0578 · Cited by 97
“Thus, mTOR inhibition revealed its impact on cellular function and cell growth (16-19).”
BackgroundmRNA Translation and Energy Metabolism in Cancer: The Role of the MAPK and mTORC1 Pathways
Topisirovic, I., & Sonenberg, N. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010785 · Cited by 92
“Thus, it is not surprising that mTOR signaling is frequently deregulated in malignancies (Mamane et al. 2006; Guertin and Sabatini 2007).”
BackgroundSelf-citationeIF6 coordinates insulin sensitivity and lipid metabolism by coupling translation to transcription
Brina, D., Miluzio, A., Ricciardi, S., Clarke, K., Davidsen, P. K., Viero, G., Tebaldi, T., Offenhäuser, N., Rozman, J., Rathkolb, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9261 · Cited by 102
Tang, F., Cho, H., Pai, M., & Chen, Y.-H. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2008.05.001 · Cited by 95
“Akt is activated by extracellular stimuli in a PI-3K dependent manner and has uncovered essential roles in the control of transcription and protein translation, which impact on cell growth, survival and cell cycle progression [8].”
BackgroundKhan, K., Quispe, C., Javed, Z., Iqbal, M. J., Sadia, H., Raza, S., Irshad, A., Salehi, B., Reiner, Ž., & Sharifi‐Rad, J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01660-7 · Cited by 97
Callari, M., Cappelletti, V., Cecco, L. D., Musella, V., Miodini, P., Veneroni, S., Gariboldi, M., Pierotti, M. A., & Daidone, M. G. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1015-8 · Cited by 100
“For example, inhibition of translation targeting either EIF4E or mTOR has been proposed as a promising new therapeutic strategy [21-22] and an increased susceptibility to such treatment in MBC could be hypothesized based on our data.”
BackgroundPost-transcriptional and post-translational regulation of Bcl2
Willimott, S., & Wagner, S. D. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381571 · Cited by 85
Targeting RNA helicases in cancer: The translation trap
van Voss, M. R. H., van Diest, P. J., & Raman, V. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.006 · Cited by 99
Sulforaphane inhibits growth of phenotypically different breast cancer cells
Pawlik, A., Hać, A., Kaczyńska, A., Antosiewicz, J., & Herman-Antosiewicz, A. (2013) · European Journal of Nutrition · doi:10.1007/s00394-013-0499-5 · Cited by 95
“phosphorylates the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), an inhibitor of cap-dependent translation, and the S6 kinase 1 which positively regulates different stages of protein synthesis [38].”
BackgroundProteasome inhibition: A new therapeutic strategy to cancer treatment
Wu, W. K. K., Cho, C. H., Lee, C. W., Wu, K., Fan, D., Yu, J. Q., & Sung, J. J. �. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.12.002 · Cited by 93
Fournier, M., Coudert, L., Mellaoui, S., Adjibade, P., Gareau, C., Côté, M., Sonenberg, N., Gaudreault, R. C., & Mazrouï, R. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01517-12 · Cited by 102
“Consequently, targeting mTORC1 signaling inhibits eIF4E activity and associated tumorigenesis (39, 40, 42, 46, 47).”
BackgroundSelf-citationAGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B
van Gorp, A. G. M., van der Vos, K. E., Brenkman, A. B., Bremer, A., van den Broek, N. J. F., Zwartkruis, F. J. T., Hershey, J. W. B., Burgering, B. M. T., Calkhoven, C. F., & Coffer, P. J. (2008) · Oncogene · doi:10.1038/onc.2008.367 · Cited by 98
“Regulation of protein translation is crucial for the specific expression of proteins important for development, differentiation, cell growth and apoptosis (Holland et al., 2004b; Mamane et al., 2006).”
BackgroundSingh, J. C., Novik, Y., Stein, S., Volm, M. D., Meyers, M., Smith, J. A., Omene, C. O., Speyer, J. L., Schneider, R. J., Jhaveri, K. L., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3634 · Cited by 95
“Through this pathway, mTOR plays a key role in the regulation of many cellular processes, including cell proliferation, survival, and apoptosis [13].”
BackgroundYap, T. A., Walton, M. I., Hunter, L.-J. K., Valenti, M. R., Brandon, A. D. H., Eve, P. D., Ruddle, R. R., Heaton, S. P., Henley, A. T., Pickard, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0760 · Cited by 89
Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway
Bermúdez, O. M., Marchetti, S., Pagès, G., & Gimond, C. (2008) · Oncogene · doi:10.1038/sj.onc.1211040 · Cited by 86
“The latter is also regulated by molecular players of the mTOR pathway (Averous and Proud, 2006; Mamane et al., 2006).”
BackgroundFujita, K. A., Toyoshima, Y., Uda, S., Ozaki, Y.-I., Kubota, H., & Kuroda, S. (2010) · Science Signaling · doi:10.1126/scisignal.2000810 · Cited by 84
Clippinger, A. J., Maguire, T. G., & Alwine, J. C. (2011) · Journal of Virology · doi:10.1128/jvi.01913-10 · Cited by 92
“formation of translation initiation complexes (21); this includes”
BackgroundEGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors
Dobashi, Y., Suzuki, S., Sato, E., Hamada, Y., Yanagawa, T., & Ooi, A. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.104 · Cited by 93
Recchia, A. G., Musti, A. M., Lanzino, M., Panno, M. L., Turano, E., Zumpano, R., Belfiore, A., Andò, S., & Maggiolini, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.004 · Cited by 82
RetractedArtero‐Castro, A., Callejas, F. D. B., Castellví, J., Kondoh, H., Carnero, A., Fernández-Marcos, P. J., Serrano, M., y Cajal, S. R., & LLeonart, M. E. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01386-08 · Cited by 87
“In contrast to the activation caused by S6 phosphorylation, 4E-BP1 phosphorylation produces an inactive protein that releases other transcription factors responsible for initiating translation (29).”
BackgroundYao, C., Ni, Z., Gong, C., Zhu, X., Wang, L., Xu, Z., Zhou, C., Li, S., Zhou, W., Zou, C., et al. (2018) · Autophagy · doi:10.1080/15548627.2018.1489946 · Cited by 85
Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies
Bilanges, B., & Stokoe, D. (2007) · Oncogene · doi:10.1038/sj.onc.1210431 · Cited by 95
“…and neck, liver, colon, bronchioalveolar and breast cancer (for a complete review, see Ruggero and Pandolfi, 2003; De Benedetti and Graff, 2004; Mamane et al., 2006; Figure 3), conferring to eIF4E the status of a valuable prognostic marker (Chen et al., 2004; Byrnes et al., 2006; Zhou et al.,…”
BackgroundmTOR Signaling Confers Resistance to Targeted Cancer Drugs
Guri, Y., & Hall, M. N. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.006 · Cited by 85
Byun, H.-O., Lee, Y.-K., Kim, J.-M., & Yoon, G. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.11.122 · Cited by 83
“phatidylinositol 3-kinase (PI3K), an upstream activator of mTOR (43-45).”
BackgroundJaiswal, N., Gavin, M., Loro, E., Sostre‐Colón, J., Roberson, P. A., Uehara, K., Rivera‐Fuentes, N., Neinast, M., Arany, Z., Kimball, S. R., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12846 · Cited by 79
Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
Nardella, C., Carracedo, A., Alimonti, A., Hobbs, R. M., Clohessy, J. G., Chen, Z., Egia, A., Fornari, A., Fiorentino, M., Loda, M., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000189 · Cited by 78
Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
Herschbein, L., & Liesveld, J. L. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.11.006 · Cited by 86
Hać, A., Hofman, D., Konopa, G., & Herman-Antosiewicz, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.05.020 · Cited by 82
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
Payne, S. N., Maher, M. E., Tran, N. H., Van De Hey, D. R., Foley, T. M., Yueh, A. E., Leystra, A. A., Pasch, C. A., Jeffrey, J. J., Clipson, L., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.28 · Cited by 72
CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT
Chaudhury, A., Cheema, S. A., Fachini, J. M., Kongchan, N., Lu, G., Simon, L. M., Wang, T., Mao, S., Rosen, D. G., Ittmann, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13362 · Cited by 77
“Consistent with reports demonstrating the widespread role of post-transcriptional regulation in gene expression and function 4 , two themes have emerged regarding the role of translational control in other aspects of carcinogenesis 5,6 .”
Elia, A., Constantinou, C., & Clemens, M. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210678 · Cited by 79
“Thus the phosphorylation of both eIF4E and 4E-BP1 that occurs in response to mitogenic and growth-promoting stimuli (Proud, 2002; Mamane et al., 2006) may have opposite consequences for the stability and levels of these two proteins.”
BackgroundInfluentialPassacantilli, I., Frisone, P., Paola, E. D., Fidaleo, M., & Paronetto, M. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx831 · Cited by 80
Zhu, M., Miao, S., Zhou, W., Elnesr, S. S., Dong, X., & Zou, X. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112091 · Cited by 74
Parisi, F., Riccardo, S., Daniel, M., Saqcena, M., Kundu, N., Pession, A., Grifoni, D., Stocker, H., Tabak, E. G., & Bellosta, P. (2011) · BMC Biology · doi:10.1186/1741-7007-9-65 · Cited by 81
“TORC1 is a central node for the regulation of anabolic and catabolic processes and contains the central enzyme Rheb-GTPase, which responds to amino acids by activating TOR kinase to induce phosphorylation of p70-S6K and 4E-BP1 [14,15].”
BackgroundMiR-424/503-Mediated Rictor Upregulation Promotes Tumor Progression
Oneyama, C., Kito, Y., Asai, R., Ikeda, J., Yoshida, T., Okuzaki, D., Kokuda, R., Kakumoto, K., Takayama, K., Inoue, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080300 · Cited by 71
“kinase (S6K) and 4E binding protein 1 (4E-BP1) [8,9].”
BackgroundPhosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma
O'Reilly, K. E., Warycha, M. A., Davies, M. A., Rodrik-Outmezguine, V. S., Zhou, X. K., Yee, H. T., Polsky, D., Pavlick, A. C., Rosen, N. X., Bhardwaj, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2336 · Cited by 71
Blancquaert, S., Wang, L., Paternot, S., Coulonval, K., Dumont, J. E., Harris, T. E., & Roger, P. P. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0087 · Cited by 68
“such as those of c-myc and cyclin D1 (88, 89, 94).”
BackgroundRahmouni, K. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06425 · Cited by 81
mLST8 Promotes mTOR-Mediated Tumor Progression
Kakumoto, K., Ikeda, J., Okada, M., Morii, E., & Oneyama, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119015 · Cited by 77
“mTORC1 is activated by diverse stimuli such as nutrients and growth factors and also by the PI3K–AKT pathway, and the complex controls cell growth by regulating protein synthesis via phosphorylation of its downstream substrates, ribosomal S6 kinase (S6K) and 4E-binding protein 1 (4E-BP1) [5, 6].”
BackgroundMitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival
Wang, Y., Begley, M., Li, Q., Huang, H., Lako, A., Eck, M. J., Gray, N. S., Mitchison, T. J., Cantley, L. C., & Zhao, J. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606862113 · Cited by 76
“MELK (full-length) B 4 F I e p (S406) MELK (full-length) MELK (1-340) Flag-eIF4B wt Flag-eIF4B (S406A) + + + + + + + + + +”
BackgroundRSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth
Romeo, Y., Moreau, J., Zindy, P.-J., Saba-El-Leil, M., Lavoie, G., Dandachi, F., Baptissart, M., Borden, K. L. B., Meloche, S., & Roux, P. P. (2013) · Oncogene · doi:10.1038/onc.2012.312 · Cited by 63
Klümpen, H., Beijnen, J. H., Gurney, H., & Schellens, J. H. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0196 · Cited by 76
Tuberous sclerosis complex: Recent advances in manifestations and therapy
Wataya‐Kaneda, M., Uemura, M., Fujita, K., Hirata, H., Osuga, K., Kagitani‐Shimono, K., & Nonomura, N. (2017) · International Journal of Urology · doi:10.1111/iju.13390 · Cited by 78
Elghazi, L., Balcázar, N., Blandino-Rosano, M., CRAS-MÉNEUR, C. M. H., Fátrai, S., Gould, A. P., Chi, M. M.-Y., Moley, K. H., & Bernal‐Mizrachi, E. (2010) · Diabetes · doi:10.2337/db09-0851 · Cited by 69
“Growing evidence suggests that not only fat consumption, but also protein intake and an increase in plasma amino acid concentration, contribute to the development of glucose intolerance, insulin resistance, and type 2 diabetes (20,21).”
BackgroundVelásquez, C., Cheng, E., Shuda, M., Lee-Oesterreich, P. J., von Strandmann, L. P., Gritsenko, M. A., Jacobs, J., Moore, P. S., & Chang, Y. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607768113 · Cited by 71
Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
Chiong, E., Lee, I.-L., Dadbin, A., Sabichi, A. L., Harris, L. D., Urbauer, D. L., McConkey, D. J., Dickstein, R. J., Cheng, T., & Grossman, H. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3202 · Cited by 76
“It is known that the downstream effectors of mTOR are 4EBP1 and S6 kinase 1 (S6K1), both of which are regulators of protein translation (7, 9).”
InfluentialTrading translation with RNA-binding proteins
Abaza, I., & Gebauer, F. (2008) · RNA · doi:10.1261/rna.848208 · Cited by 62
“Misregulation of global or mRNAspecific translation contributes to disease (Mamane et al. 2006; Kozma et al. 2007; Wiemer 2007).”
Grimshaw, K. M., Hunter, L.-J. K., Yap, T. A., Heaton, S. P., Walton, M. I., Woodhead, S. J., Fazal, L., Reule, M., Davies, T. G., Seavers, L. C. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0986 · Cited by 67
“Cyclin D1 expression and thus cell cycle progression is regulated at the posttranslational level by GSK3β and also by protein translation through p70S6K via mTOR (12).”
BackgroundRodrigues, D. A., Gomes, C. M., & Costa, I. M. C. (2012) · Anais Brasileiros de Dermatologia · doi:10.1590/s0365-05962012000200001 · Cited by 69
Amornphimoltham, P., Leelahavanichkul, K., Molinolo, A., Patel, V., & Gutkind, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0703 · Cited by 63
Metformin and Colorectal Cancer
Higurashi, T., & Nakajima, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00622 · Cited by 68
“Downstream targets of mTOR signaling include proteins that control translational machinery, including the ribosomal protein S6 kinases (S6K) that regulate the initiation and elongation phases of translation (34).”
BackgroundKapoor, V., Zaharieva, M. M., Das, S. N., & Berger, M. R. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.12.032 · Cited by 67
Cemeus, C., Zhao, T., Barrett, G. M., Lorimer, I. A. J., & Dimitroulakos, J. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9627-0 · Cited by 65
“For example, inhibition of mTOR, a downstream target of AKT that regulates protein translation, cell growth and survival [31], with rapamycin in combination with EGFR tyrosine kinase inhibitors induced synergistic growth inhibition in PTEN deficient glioblastoma cells [21].”
BackgroundThe impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival
William, W. N., Kim, J.-S., Liu, D. D., Solis, L. M., Behrens, C., Lee, J. J., Lippman, S. M., Kim, S., Hong, W. K., Wistuba, I. I., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr036 · Cited by 63
Melnik, B. C., John, S. M., Carrera‐Bastos, P., & Cordain, L. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-74 · Cited by 69
“Genetic findings in mouse models implicate mTORC1 hyperactivation in both PCa initiation and progression [82-87].”
Glatter, T., Schittenhelm, R. B., Rinner, O., Roguska, K., Wepf, A., Jünger, M. A., Köhler, K., Jevtov, I., Choi, H., Schmidt, A., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.79 · Cited by 63
“In human cells, it has been shown that mTOR can phosphorylate 4E-BP1, which causes dissociation from eIF-4E and subsequent release of translational suppression (Mamane et al, 2006).”
BackgroundYang, H., Wang, J., Fan, J., Zhang, Y., Zhao, J., Dai, X., Liu, Q., Shen, Y., Liu, C., Sun, W., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.12.008 · Cited by 64
“The mTOR in turn involves the regulation of several important proliferative and angiogenic factors, including the translation of VEGF (Mamane et al., 2006).”
BackgroundSmall tumor antigen of polyomaviruses: Role in viral life cycle and cell transformation
Khalili, K., Sariyer, I. K., & Safak, M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21326 · Cited by 70
“Variousmutants of this domain including a short deletion (d17-27) or amino acid substitution, D44N mutant, exhibited various degrees of penetration for transformation (Chen and Paucha, 1990; Marsilio et al., 1991; Sullivan et al., 2000, 2001).”
BackgroundWang, X., & Proud, C. G. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01512-07 · Cited by 76
“The initiation factor eIF4E is a well-studied target for control by mTORC1 and amino acids, its availability being regulated by the 4E-BPs (24, 44), and is widely considered to play a pivotal role in the control of translation initiation (30, 41).”
BackgroundYamanaka, K., Petrulionis, M., Lin, S., Gao, C., Galli, U., Richter, S., Winkler, S., Houben, P., Schultze, D. P., Hatano, E., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.150 · Cited by 66
“kinase (JNK) pathway to induce apoptosis in absence of p53, dependent on 4E-BP1 [35], which suggests everolimus can induce apoptosis in tumors with p53 mutation [36].”
BackgroundCho, S.-J., Rossi, A., Jung, Y.-S., Yan, W., Liu, G., Zhang, J., Zhang, M., & Chen, X. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221242110 · Cited by 59
“One possibility is via mechanistic target of rapamycin (mTOR) kinase, which can be activated by growth signals and regulates mRNA translation via assembly of eukaryotic translation initiation factor (eIF) complex (30).”
BackgroundThe Regulatory Effects of mTOR Complexes in the Differentiation and Function of CD4 + T Cell Subsets
Wang, P., Zhang, Q., Tan, L., Xu, Y., Xie, X., & Zhao, Y. X. (2020) · Journal of Immunology Research · doi:10.1155/2020/3406032 · Cited by 71
“13 (ATG13) in its downstream [9 – 12].”
Modulation of Host Cell Stress Responses by Human Cytomegalovirus
Alwine, J. C. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-77349-8_15 · Cited by 64
Jackson, J. B., & Pallas, D. C. (2012) · Neoplasia · doi:10.1593/neo.12768 · Cited by 60
“Given that S6K can be activated by Akt through the mTOR pathway [45,46], much of the LCMT-1–dependent activation of the S6K pathway might be a consequence of Akt activation.”
BackgroundmTOR in health and in sickness
Liko, D., & Hall, M. N. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1326-7 · Cited by 67
“Extensive literature points to 4EBP1 phosphorylation as the major effector of mTOR in tumorigenesis, as it promotes selective translation of a specific class of oncogenic proteins [99, 27, 100].”
Metadata
- Authors
- Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N.
- Affiliations
- McGill University (CA)
- Corresponding author
- Sonenberg, N
- ORCID
- Sonenberg, N
- Venue
- Oncogene
- Published
- 2006-10-16
- Volume
- 25
- Issue
- 48
- Pages
- 6416-6422
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2165848665
- Cited by
- 607
- References
- 79
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 28 · 2022: 14 · 2021: 7 · 2020: 23 · 2019: 16 · 2018: 32 · 2017: 26 · 2016: 28 · 2015: 41 · 2014: 41 · 2013: 40 · 2012: 41
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mTOR, mRNA translation, translation initiation, PI3K/AKT/mTOR pathway, 4E-BP, S6K, cap-dependent translation, cancer therapy, nutrient signaling, cell growth
- MeSH terms
- Animals, Gene Expression Regulation, Humans, Mammals, Models, Genetic, Neoplasms, Peptide Chain Initiation, Translational, Protein Kinases, Signal Transduction, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.